These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27401411)

  • 21. In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron capture therapy.
    Liu L; Barth RF; Tjarks W; Soloway AH; Anisuzzaman AK
    Anticancer Res; 1996; 16(1):113-20. PubMed ID: 8615595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.
    Wang P; Zhen H; Jiang X; Zhang W; Cheng X; Guo G; Mao X; Zhang X
    BMC Cancer; 2010 Dec; 10():661. PubMed ID: 21122152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boronated dipeptide borotrimethylglycylphenylalanine as a potential boron carrier in boron neutron capture therapy for malignant brain tumors.
    Takagaki M; Powell W; Sood A; Spielvogel BF; Hosmane NS; Kirihata M; Ono K; Masunaga SI; Kinashi Y; Miyatake SI; Hashimoto N
    Radiat Res; 2001 Jul; 156(1):118-22. PubMed ID: 11418080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy.
    Sun T; Li Y; Huang Y; Zhang Z; Yang W; Du Z; Zhou Y
    Oncotarget; 2016 Jul; 7(28):43095-43108. PubMed ID: 27191269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT.
    Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Asano T; Kirihata M; Ono K; Kuroiwa T
    J Neurooncol; 2006 Jul; 78(3):227-32. PubMed ID: 16557351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas.
    Tjarks W; Barth RF; Rotaru JH; Adams DM; Yang W; Kultyshev RG; Forrester J; Barnum BA; Soloway AH; Shore SG
    Anticancer Res; 2001; 21(2A):841-6. PubMed ID: 11396173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats.
    Kanemitsu T; Kawabata S; Fukumura M; Futamura G; Hiramatsu R; Nonoguchi N; Nakagawa F; Takata T; Tanaka H; Suzuki M; Masunaga SI; Ono K; Miyatake SI; Nakamura H; Kuroiwa T
    Radiat Environ Biophys; 2019 Mar; 58(1):59-67. PubMed ID: 30474719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of boron distribution in vivo for boron neutron capture therapy using two different boron compounds by secondary ion mass spectrometry.
    Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Okabe M; Kirihata M; Ono K; Kuroiwa T
    Radiat Res; 2007 Jan; 167(1):102-9. PubMed ID: 17214510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy.
    Miyata S; Kawabata S; Hiramatsu R; Doi A; Ikeda N; Yamashita T; Kuroiwa T; Kasaoka S; Maruyama K; Miyatake S
    Neurosurgery; 2011 May; 68(5):1380-7; discussion 1387. PubMed ID: 21273928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.
    Harada T; Hirose K; Wada Y; Sato M; Ichise K; Aoki M; Kato T; Takeda K; Takai Y
    J Radiat Res; 2020 Jul; 61(4):524-534. PubMed ID: 32367141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages.
    Miyatake S; Kawabata S; Kajimoto Y; Aoki A; Yokoyama K; Yamada M; Kuroiwa T; Tsuji M; Imahori Y; Kirihata M; Sakurai Y; Masunaga S; Nagata K; Maruhashi A; Ono K
    J Neurosurg; 2005 Dec; 103(6):1000-9. PubMed ID: 16381186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
    Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
    Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
    Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative evaluation of boron neutron capture therapy (BNCT) drugs for boron delivery and retention at subcellular-scale resolution in human glioblastoma cells with imaging secondary ion mass spectrometry (SIMS).
    Chandra S; Ahmad T; Barth RF; Kabalka GW
    J Microsc; 2014 Jun; 254(3):146-56. PubMed ID: 24684609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading.
    Capuani S; Gili T; Bozzali M; Russo S; Porcari P; Cametti C; Muolo M; D'Amore E; Maraviglia B; Lazzarino G; Pastore FS
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S34-6. PubMed ID: 19375337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma:
    Alamón C; Dávila B; García MF; Nievas S; Dagrosa MA; Thorp S; Kovacs M; Trias E; Faccio R; Gabay M; Zeineh N; Weizman A; Teixidor F; Viñas C; Gavish M; Cerecetto H; Couto M
    Mol Pharm; 2023 May; 20(5):2702-2713. PubMed ID: 37013916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry.
    Flieger S; Takagaki M; Kondo N; Lutz MR; Gupta Y; Ueda H; Sakurai Y; Moran G; Kempaiah P; Hosmane N; Suzuki M; Becker DP
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption.
    Barth RF; Yang W; Rotaru JH; Moeschberger ML; Joel DD; Nawrocky MM; Goodman JH; Soloway AH
    Cancer Res; 1997 Mar; 57(6):1129-36. PubMed ID: 9067283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model.
    Kashiwagi H; Kawabata S; Yoshimura K; Fukuo Y; Kanemitsu T; Takeuchi K; Hiramatsu R; Nishimura K; Kawai K; Takata T; Tanaka H; Watanabe T; Suzuki M; Miyatake SI; Nakamura H; Wanibuchi M
    Invest New Drugs; 2022 Apr; 40(2):255-264. PubMed ID: 34816337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
    Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.